MAPT and Alzheimer disease: One hypothetical possibility raised by our results is that therapies targeting the processes that lead to production of P‐tau217 may break the link between build‐up of aggregated Aβ and tau and thereby reduce atrophy and cognitive decline in AD (which are both strongly associated with tau pathology (Mattsson et al,2019; Ossenkoppele et al,2019)).